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INTRODUCTION 
 
 
With approximately 1.4 million deaths per year, lung 
cancer is the leading cause of cancer-related deaths. 
The term lung cancer represents a rather heterogeneous 
group of diseases, including conditions of varying etiology 
and molecular background. As a result of a new approach 
to classification based on novel molecular biological 
methods, the therapeutically relevant main histological 
categories (small cell lung cancer (SCLC), 
adenocarcinoma and squamous cell carcinoma) may 
undergo significant changes in the future. 
In addition, identification of the so called ”driver” 
oncogenic mutations plays a decisive role in the 
development of different tumor types and open the way to 
targeted biological therapies. Different amino acid-
specific subtype mutations lead to a different downstream 
signaling and drug sensitivity. Patient responses to 
chemotherapy within a molecular subgroup may also vary. 
However, the clinical consequence of amino-acid specific 
subtypes of these mutations is far less understood. 
Molecular epidemiology and clinicopathological 
characteristics of tumors play an important role in therapy 
decision and help tumor boards to select patients for 
molecular analysis. A major obstacle to draw a definitive 
conclusion is the vast heterogeneity of the studies in terms 
of ethnicity, histological subtype, tumor stage and 
treatment modality.  
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Therefore, in the current studies, we analyzed a well-
defined Caucasian, advanced-stage patient cohort within a 
four-year-long period.  
In this thesis, we discuss the epidemiology and clinical 
relevance of subtype-specific driver oncogenic mutations, 
especially in an era where there is an urgent, unmet need 
to include more lung cancer patients in targeted therapy 
and other effective treatment regimens.  
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OBJECTIVES 
 
A number of clinicopathological factors influences the 
incidence and clinical consequence of oncogenic driver 
mutations. Therefore, in this thesis, we aimed to 
investigate the epidemiology and clinical relevance of 
subtype-specific KRAS and EGFR mutations in lung 
adenocarcinoma. 
 
1. In advanced-stage lung adenocarcinoma, the clinical 
significance of amino acid substitution-specific KRAS 
mutational status in terms of tumor progression after 
chemotherapy and OS has not yet been clearly established. 
Therefore, in order to better understand the influence of 
KRAS mutations in this setting, we analyzed a large cohort 
of Caucasian patients with unresected stage III-IV lung 
adenocarcinoma who were treated with platinum-based 
chemotherapy. 
 
2. Furthermore, in lung adenocarcinoma, the clinical 
significance of rare EGFR mutations has not yet been fully 
understood [64, 65]. Therefore, we analyzed a large cohort 
of Caucasian patients with known KRAS and EGFR 
mutational status to compare the epidemiology and 
clinical consequence of rare and classic EGFR mutations. 
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3. There is limited data available regarding the influence 
of KRAS mutation on the organ specificity of lung 
adenocarcinoma dissemination. Therefore, the aim of our 
study was to investigate the metastatic site-specific 
incidence and prognostic value of KRAS mutation in lung 
adenocarcinoma patients. 
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METHODS 
 
Study Population 
 
Consecutive patients (n=1247) with cytologically or 
histologically confirmed, advanced lung adenocarcinoma 
evaluated at the National Koranyi Institute of 
Pulmonology and at the Department of Pulmonology, 
Semmelweis University between 2009-2013 were 
analyzed in this retrospective study.  
 
Based on the inclusion criteria, we set up three patient 
cohorts. In the study cohorts, the molecular analysis was 
performed for potential EGFR-TKI therapy indication.  
Cohort #1 (n=505 patients) was dedicated to understand 
the clinical role of amino acid-specific subtype KRAS 
mutations in lung adenocarcinoma. The cohort #2 (n=814 
patients) focused on the epidemiology and clinical 
relevance of rare EGFR mutations. The combined cohort 
(n=903) investigated the site-specific variations in KRAS 
status according to metastatic sites. 
 
Mutation Analysis 
 
Genomic DNA was isolated from formalin-fixed paraffin-
embedded (FFPE) tumor tissues. Mutations in KRAS and 
EGFR were investigated via polymerase chain reaction 
restriction fragment length polymorphism and by Sanger 
(direct) sequencing. 
  
7 
 
Treatments 
 
According to our inclusion criteria, in cohort #1 all 
patients were treated with platinum-based doublet 
regimen. Indications for EGFR tyrosine kinase inhibitor 
(TKI) therapy in cohort #2 were: advanced lung 
adenocarcinoma patients received in 2nd and 3rd lines 
erlotinib with KRAS wild-type tumor, meanwhile 1st line 
gefitinib was available for Patients with activating EGFR 
mutation.  
 
Statistical Methods 
 
All statistical analyses were performed using the SPSS 
Statistics 18.0 package. 
 
In vitro experiments 
 
Eight human NSCLC cell lines were used in the 
experiments. The antiproliferative effect of zoledronic 
acid (ZA) treatment was evaluated by clonogenic assay. 
Briefly, 1000 cells were seeded in six well plates and 
treated 1, 2, 8, and 32 μM ZA for 10 days. Finally, cells 
were fixed with trichloroacetic acid (10%) and stained with 
Sulforhodamine B. The protein-bound dye was dissolved in 10 
mM Tris and the optical density (OD) was determined. 
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RESULTS 
 
Molecular epidemiology of driver oncogenic 
mutations in advanced lung adenocarcinoma 
 
KRAS mutation rate in cohort #1, 2, and combined cohort 
was 33%, 28%, and 29%, respectively. Furthermore, we 
found exon 2, codon 12 and 13 KRAS mutations in 93% 
and 7%, respectively. The number of the major KRAS 
subtypes in cohort #1 was 61 (39%) G12C, 29 (18%) G12V, 27 
(17%) G12D, and 8 (5%) G12A. In 31 cases rare KRAS codon 
12 and 13 subtype mutations were identified. 
In cohort #2, there were 5% classic EGFR mutant 6% rare 
EGFR mutant (non-classic mutation where amino acid 
change occurs), and 3% of the patients carried 
synonymous (silent) EGFR mutations (non-classic 
mutations without amino-acid change in EGFR). Fifty-
nine percent of the cases was classified as KRAS/EGFR 
double WT. 
Of note, in five patients, the G719x or L861Q rare 
sensitizing mutation was identified. Based on the 
Catalogue of Somatic Mutations in Cancer (COSMIC) 
data base, we found synonymous and rare EGFR gene 
mutations already published in lung cancer 
(N=33mutations) or in malignancies of other organs 
(N=20 mutations). Additionally, 45 previously 
unpublished novel mutations were identified. 
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The T790M resistance mutation was not detected in any 
patients. Interestingly, in case of 16 patients, 39 mutations 
were identified within a complex mutation pattern (at least 
two different EGFR mutations within a single sample). 
 
Clinicopathological characteristics of lung 
adenocarcinoma patients 
 
In all cohort studies, KRAS mutational status was 
significantly associated with smoking. Importantly, the 
amino acid-specific mutation subtype analysis identified 
G12V KRAS mutation as more frequent in never-smokers 
than among former and current (or ever) –smokers. 
We found that rare EGFR mutations were associated with 
smoking (vs. classic EGFR mutations). 
Among the 903 consecutive lung adenocarcinoma patients 
identified, 500 cases were metastatic at the time of 
diagnosis. We found 362 (72%) single-organ and 138 
(28%) multiple-organ metastatic cases. The most frequent 
metastatic sites included lung (45.6%), bone (26.2%), 
adrenal gland (17.4%), brain (16.8%), pleura (15.6%), and 
liver (11%). 
There was no difference in the KRAS mutation incidence 
between the single- and multiple-organ or metastatic 
(28.6%) and non-metastatic cases (28%). 
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Importantly, patients with brain (29%), bone (28%) or 
adrenal gland (33%) metastases demonstrated similar 
KRAS mutation frequencies. However, pulmonary 
metastatic cases demonstrated significantly increased 
KRAS mutation frequency when compared to those with 
extrapulmonary metastases (35% and 26.5%, respectively) 
In contrast, pleural dissemination and liver metastasis 
associated with decreased KRAS mutation incidence (vs. 
all other metastatic sites; 17% (P<0.001) and 16% 
(P=0.0023), respectively). 
 
Prognostic factors in advanced lung adenocarcinoma 
 
We found no difference in overall survival (OS) based on 
smoking habits in cohort #1. In contrast, ever-smoker 
status was a significant prognostic factor in cohort #2 for 
reduced OS (vs. never-smoker; P=0.006). Disease stage 
at diagnosis was prognostic in both cohorts.  
Of note, we found no effect of KRAS mutational status of 
tumors on OS in neither cohorts. (There was no difference 
between KRAS codon 12, codon 13 mutant or KRAS WT 
patients in OS. Also, we found no difference in OS 
according to KRAS mutation status in patients neither 
presented with single nor with multiple-organ spreads. 
However, classic EGFR mutation conferred a significant 
benefit for OS as compared to EGFR and KRAS WT or 
KRAS mutation. 
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In contrast, there was no significant difference in the OS 
of rare EGFR mutation positive patients compared to 
patients with WT KRAS/EGFR or with mutant KRAS.  
Next, we investigated the impact of KRAS mutation on OS 
in different organ-specific metastases in lung 
adenocarcinoma patients. We found a clinically relevant 
and significant increase in OS in patients presented with 
KRAS WT bone metastasis (vs. KRAS mutants, median OS 
9.7 vs. 3.7 months; P=0.003). Importantly, we found no 
statistically significant information in any other organ-
specific comparison. 
 
Therapeutic consequences of subtype-specific 
oncogenic mutations in advanced lung 
adenocarcinoma. 
 
We evaluated the RR and PFS of platinum-based 
chemotherapy treated locally advanced or metastatic lung 
adenocarcinoma patients. There was no difference in RR 
or PFS among tumors carrying KRAS codon 12, codon 13 
mutations or KRAS WT. We found that G12V KRAS 
mutant patients are significantly more frequent among 
never-smokers than other codon 12 KRAS mutant (G12x) 
cases. This subgroup of patients had a non-significantly 
increased RR to platinum-based chemotherapy (P=0.077). 
Furthermore, there was a non-significant modest increase 
in PFS. (233 vs. 175 days).  
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Next, we evaluated TKI-treated advanced lung 
adenocarcinoma patients with classic and rare EGFR. 
There was a significantly increased RR among patients 
with classic EGFR mutations compared to those with rare 
EGFR mutations (RR 71% vs 37%, respectively; 
P=0.039). 
 
Oncogenic driver dependent in vitro zoledronic acid 
sensitivity of lung adenocarcinoma cells 
 
In order to investigate the factors contributing the poor 
prognosis of KRAS mutant bone metastatic patients we 
performed experiments to test the sensitivity of KRAS 
mutant and KRAS WT lung adenocarcinoma cells to ZA, a 
frequently administered therapeutic regimen in bone 
metastatic patients. 
Therefore, we performed clonogenic assay in lung 
adenocarcinoma cells following bisphosphonate treatment 
with ZA. All cell lines demonstrated sensitivity. 
Interestingly, resistance was not found in any of the cell 
lines including KRAS mutant cells.  
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CONCLUSIONS 
 
Considering the results of this thesis the following main 
conclusions can be drawn in order to answer the questions 
formulated as the aims of the thesis. 
 
1. The G12V subtype of KRAS mutations is associated 
with different clinicopathological characteristics and 
patients carrying G12V mutations may show increased 
response to platinum-based doublet regimens. 
 
2.  In our study, the majority of rare EGFR mutations was 
associated with smoking, shorter overall survival, and 
decreased EGFR-TKI response when compared with 
classic EGFR mutations. Studies characterizing the 
TKI sensitizing effect of individual rare mutations are 
indispensable to prevent the exclusion of patients with 
sensitizing rare EGFR mutations who may benefit 
from EGFR-TKI therapy. 
 
3.  Our study is the first that showed metastatic site-
specific variation of the prognostic value of KRAS 
status in lung adenocarcinoma. We suggest the KRAS 
mutation may have important implications for 
diagnostic strategies and treatment decisions. 
  
14 
 
4. Based on our results, we suggest that KRAS mutation 
has a strong prognostic value in bone metastatic 
patients associated with decreased OS. Nevertheless, 
further studies are needed to evaluate whether KRAS 
mutation can be used to risk stratify patients with bone 
metastasis or even might predict response to various 
treatment options for bone metastatic patients.  
 
5. The effect of zoledronic acid treatment on the 
clonogenic potential of lung adenocarcinoma cell was 
not dependent on KRAS mutant status and thus 
prenylation inhibition may not depend on the driver 
oncogenic mutations present in the tumor. 
Importantly, prenylation inhibition may be able to 
inhibit both KRAS mutant and KRAS wild-type lung 
cancer cells. The worse outcome of bone metastatic 
KRAS mutant patients in our combined cohort might 
not be due to the decreased sensitivity of tumor cells 
to zoledronic acid. 
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